<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513342</url>
  </required_header>
  <id_info>
    <org_study_id>JSLCG-001</org_study_id>
    <nct_id>NCT02513342</nct_id>
  </id_info>
  <brief_title>Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma</brief_title>
  <official_title>Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing NingQi Medicine Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing NingQi Medicine Science and Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection&#xD;
      pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance&#xD;
      treatment., and explore the predicted biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to month 36</time_frame>
    <description>FS is a tumor progression or death time of a patient who has an objective record on the date of enrollment. PFS calculation end if the patient was lost, unknow death , or other anti tumor therapy was used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall remission rate(ORR)</measure>
    <time_frame>change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate （DCR）</measure>
    <time_frame>change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Advanced Lung Squamous Carcinoma</condition>
  <arm_group>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel+Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Endostar 30mg continuous intravenous injection pump,d1-d7；</description>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>d4 Docetaxel，75（mg/m2），iv；</description>
    <arm_group_label>Docetaxel+Cisplatin</arm_group_label>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>d4，cisplatin，75（mg/m2），iv；</description>
    <arm_group_label>Docetaxel+Cisplatin</arm_group_label>
    <arm_group_label>Endostar+Docetaxel+Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cytological and histological confirmation（Do not accept single sputum cytology in the&#xD;
             diagnosis of patients） in patients diagnosed of lung squamous carcinoma;&#xD;
&#xD;
          2. According to a new IASLC2009 lung cancer TNM stages judged stage IIIB or IV non-small&#xD;
             cell lung cancer.&#xD;
&#xD;
          3. Must have at least one evaluated lesion,according to the RRECIST version 1.1 standard&#xD;
             (the longest diameter on spiral CT at least 10 mm,the longest diameter on plain CT at&#xD;
             least 20 mm);&#xD;
&#xD;
          4. Male or female, age between 18 and 75 years old ;&#xD;
&#xD;
          5. ECOG PS 0~1；&#xD;
&#xD;
          6. Expected survival period ≥ 3 months or more&#xD;
&#xD;
          7. Enough blood function: absolute neutrophil count (ANC)≥2 x 109 / L and the platelet&#xD;
             count≥ 100 x 109 / L and hemoglobin ≥9 g/dL;&#xD;
&#xD;
          8. Enough liver function: total bilirubin acuities≤the upper limit of normal (ULN); AST&#xD;
             and ALT acuities ≤2.5 times of the upper limit of normal (ULN); Alkaline phosphatase&#xD;
             ≤5 times of the upper limit of normal(ULN);&#xD;
&#xD;
          9. Enough renal function：serum creatinine ≤the limit of normal(ULN) or calculated&#xD;
             creatinine clearance≥60 mL/min.&#xD;
&#xD;
         10. The electrocardiogram (ecg) basicaly normal,the body had no to heal wounds&#xD;
&#xD;
         11. No previous anti-tumor drug therapy, or only received for non metastatic tumor of&#xD;
             adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the&#xD;
             study start.&#xD;
&#xD;
         12. Patients had surgery before,but have more than 4 weeks before the study star, and the&#xD;
             patient has recovered;&#xD;
&#xD;
         13. Women with cmpleted uterus before intact in the group within 28 days must have a&#xD;
             negative pregnancy test results (unles amenorrhea for 24 months). If the pregnancy&#xD;
             test from the first time for more than 7 days,the patients need for urine pregnancy&#xD;
             test(within 7 days before the first delivery).&#xD;
&#xD;
         14. Prior to biological agents, especially e. coli genetically engineered products without&#xD;
             severe allergic reactions;&#xD;
&#xD;
         15. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy, nursing mothers, or female patients with fertility but no contraception.&#xD;
&#xD;
          2. Existing serious acute infection, and can not be controlled; Or with fester sex and&#xD;
             chronic infection,or wound in delay;&#xD;
&#xD;
          3. Original serious heart disease, including: congestive heart failure, uncontroled high&#xD;
             risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart&#xD;
             disease, and resistant hypertension;&#xD;
&#xD;
          4. With uncontroled nerve, mental illness or mental disorders, compliance is poor, can't&#xD;
             cooperate and response to treatment; Uncontroled primary brain tumors or CNS&#xD;
             metastases illness, with obvious symptoms in cranial hypertension or nerve spirit;&#xD;
&#xD;
          5. With a bleeding tendency&#xD;
&#xD;
          6. Researchers believe that patients should not participate in this test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yin Qingfeng, manager</last_name>
    <phone>0086-02585632992</phone>
    <email>y_qingfeng@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhou Xiaolei, sponsor</last_name>
    <phone>0086-02585566666</phone>
    <email>zhouxiaolei@simcere.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Qingfeng, Manager</last_name>
      <phone>0086013912903257</phone>
      <email>y_qingfeng@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhou Xiaolei, Manager</last_name>
      <phone>0086013776639377</phone>
      <email>zhouxiaolei@simcere.com</email>
    </contact_backup>
    <investigator>
      <last_name>Song Yong, director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of soochow university</name>
      <address>
        <city>Soochow</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Qingfeng, mananger</last_name>
      <phone>08613912903257</phone>
      <email>y_qingfeng@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhou Xiaolei, mananger</last_name>
      <phone>08613776639377</phone>
      <email>zhouxiaolei@simcere.com</email>
    </contact_backup>
    <investigator>
      <last_name>Huang Jianan, director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endostar,Advanced lung squamous carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

